Zynerba Pharmaceuticals : January 2023 Corporate Presentation

Advancing Science.

Improving Connections.

Next-Generation Transdermal

Cannabinoid Therapeutics

NASDAQ	January 2023

ZYNE

© 2022 Zynerba Pharmaceuticals, Inc. All rights reserved.

Forward-Looking Statements

The statements in this presentation may include forward-looking statements within the meaning of the private securities litigation reform act of 1995. These statements, among other things relate to the future operations, opportunities, or financial performance of Zynerba Pharmaceuticals, Inc. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the Company's current expectations, including but not limited to the following: the Company's cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; the results, cost and timing of the Company's clinical development programs, including any delays to such clinical trials relating to enrollment or site initiation; clinical results for the Company's product candidates may not be replicated or continue to occur in the Company's ongoing

or planned clinical trials in FXS, 22q, or in any additional trials, and may not otherwise support further development in a specified indication or at all; the Company's RECONNECT trial may not be determined to be sufficient to support a submission for regulatory approval, including an NDA or MAA; actions or advice of the U.S. Food and Drug Administration or foreign regulatory agencies may affect the design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional clinical trials; the Company's ability to obtain and maintain regulatory approval for its product candidates, and the labeling under any such approval; the Company's expectations regarding its ability to obtain and adequately maintain sufficient intellectual property protection for its product candidates; the extent to which health epidemics or other outbreaks of communicable diseases, including COVID-19, could disrupt our operations or adversely affect our business and financial conditions; and the extent to which inflation or global instability, including political instability, may disrupt our business operations or our financial condition. These and other risks are described in our filings with the U.S. Securities and Exchange Commission, available at www.sec.gov. Any forward-lookingstatements that the Company makes in this presentation speak only as of the date of this presentation. The Company assumes no obligation to update forward-lookingstatements whether as a result of new information, future events or otherwise, after the date of this presentation.

© 2022 Zynerba Pharmaceuticals, Inc. All rights reserved. Zynerba and Zygel are trademarks of Zynerba Pharmaceuticals, Inc. All other trademarks are property of their respective owners.

	2	Zynerba Pharmaceuticals | Advancing Science. Improving Connections.	January 2023

A different and exciting

approach to Cannabidiol

An Orphan-Focused Neuropsychiatric, Biopharmaceutical Company

FIRST AND ONLY	LATE-STAGE
TRANSDERMAL
PIPELINE
CANNABIDIOL GEL

Permeation-enhanced		One Phase 3 clinical
		program ongoing
Patent-protected
through 2040		One additional orphan
		indication is Phase 3
Pharmaceutically		ready
manufactured; THC free

POSITIONED FOR SUCCESS

Leadership expertise in transdermal delivery, rare diseases and specialty markets

Clean balance sheet and cash runway to mid-year 2024

A different and exciting approach to Cannabidiol

	4	Zynerba Pharmaceuticals | Advancing Science. Improving Connections.	January 2023

Benefits of Our Approach to Cannabidiol

PHARMACEUTICAL MANUFACTURING

FDA regulated

Consistency of production

Purity of ingredients

No THC - not a scheduled drug by U.S. DEA

Scalable production process

TRANSDERMAL DELIVERY

Ease of application for caregivers of patients with behavioral issues

Minimizes GI side effects and reduces risk for liver toxicity

Lower risk for drug/drug interactions

Avoids conversion to THC in stomach

Provides cannabidiol plasma levels similar to oral cannabidiol (5-10 mg/kg) plasma levels

	5	Zynerba Pharmaceuticals | Advancing Science. Improving Connections.	January 2023